Zydus Lifesciences venture capital arm to acquire stake in Agenus for USD 16 million
Pennington: Zynext Ventures USA LLC, the venture capital arm of Zydus Lifesciences Limited, has entered into Securities Purchase Agreement with Agenus Inc., USA to acquire 2,133,333 shares of common stock having par value of USD 0.01 per share, representing 5.9% of the paid-up share capital of the Agenus Inc. (on fully diluted basis) at a purchase price of USD 7.50 per share aggregating to approximately USD 16 million.
Agenus Inc. is a leading US-based immuno-oncology company developing next generation therapeutics for high-unmet need cancers.
Agenus’ lead programme comprising Botensilimab (BOT) and Balstilimab (BAL), is a nextgeneration immunotherapy platform designed to strengthen and sustain the immune system’s response against tumour cells. Currently in advanced clinical trials, BOT/BAL have demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and neoadjuvant settings.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.